Kuick Research Report Gives Detailed Insight On Ongoing Rare Disease Drug Market And Highlights Ongoing Clinical TrialsDelhi, ...

An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded ...

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for ...

Biodexa has received Orphan Drug Designation in Europe for eRapa in ... Potential risks associated with the drug development process, including uncertainties regarding the success of the Phase ...

Biohaven shares plunged Thursday after the Food and Drug Administration unexpectedly delayed the review date for its rare-disease drug.

Equecabtagene Autoleucel (FUCASO), has been granted Orphan Drug Designation (ODD) by the Saudi Food and Drug Authority (SFDA) for the treatment of adult patients with relapsed or refractory ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

SHANGHAI, NANJING, China and SAN FRANCISCO, May 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and ...

Ms. Jinhua Z hang , Founder, Chairperson, and CEO of IASO Biotherapeutics, stated: "We are delighted that equecabtagene autoleucel has been grated the Orphan Drug Designation by the SFDA.